Summary.-The effects of sodium pentobarbitone anaesthesia, the presence of a tumour, and local hyperthermia to a tumour-bearing leg, on the pharmacokinetics of MISO in the mouse are reported. Analysis of MISO and its metabolite Ro 05-9963 was by high-performance liquid chromatography. The plasma kinetics of MISO were largely unaffected by any of these treatments, but hyperthermia substantially reduced tumour concentrations of the drug.
THE HYPOXIC CELL RADIOSENSITIZER misonidazole (1 -(2-nitroimidazol-1-yl)-3-methoxy propan-2-ol; Ro 07-0582 from Roche Laboratories; NSC-26 1037; MISO), which is currently undergoing clinical trials, has been shown to exhibit selective cytotoxicity to hypoxic cells (Mohindra & Rauth, 1976; Brown, 1975; Sutherland et al., 1976) . It has been further demonstrated that this cytotoxicity is enhanced by hyperthermia both in vitro Stratford & Adams, 1977) and in vivo in the mouse  GAeorge et al., 1977) . This in vivo work in the mouse has involved anaesthetizing the animal, usually with sodium pentobarbitone. Recently there has been a growing awareness that the side effects of anaesthesia can grossly affect the end-points of some experiments, for instance Saffan (the veterinary equivalent of Althesin) has been reported to increase the growth delay of a solid tumour treated with Melphalan (Peacock & Stephens, 1978) . Sodium pentobarbitone itself has been reported to alter the radiosensitivity of various tumours and normal tissues, sometinmes rendering them radioresistant (Sheldon et al., 1977; Keizer & Van Putten, 1] 976) and sometimes more radiosensitive (Hornsey et al., 1977; Hendry, 1978) . It has also been reported to have no influence on radiosensitivity (Douglas & Fowler, 1976; Paterson & Matthews, 1951) . It is therefore necessary to check the effect of an anaesthetic in any system where it has been used, and the first part of the present paper describes our investigations into the effect of sodium pentobarbitone on the pharmacokinetics of MISO.
The effect of variation in temperature on drug pharmacokinetics had not been widely studied when the subject was reviewed by Ballard in 1974 , with the conclusion that both hyperthermia and hypothermia may in some instances influence the pharmacokinetic behaviour of a drug. For example, the rate of binding of 32p Thiotepa to perfused hind limbs of dogs was shown to be higher at tissue tempera-tures of 37-2-38-90C than at 23-9-26410C (Rochlin et al., 1961) . More recently a detailed study of Adriamycin in wholebody hyperthermic (42 5°C) and control rabbits (Mimnaugh et al., 1978) revealed no difference in clearance rate of the parent drug, but significantly higher concentrations of Adriamycin and its metabolites in the skeletal muscle and duodenum of hyperthermic animals. In this paper we report investigations into the effect of local hyperthermia on the pharmacokinetics of MISO by studying plasma and tumour concentrations of MISO and its 0-demethylated metabolite, We also report on the influence of tumour size and site on concentrations, on the uniformity of distribution of MISO within tumours and on the effect of mechanical disturbance by the temperature probe detectors on MISO concentrations in tumours.
EXPERIMENTAL

Animals
Adult BALB/c mice were obtained from the breeding colony at NIMR (Mill Hill, London) and were housed in plastic cages on sawdust bedding. They were fed PRD nuts (Labsure Animal Diets, Poole, Dorset) and allowedc water ad lib. Mice weighed 20-25 g.
Turnours
The tumour used throughout this work is the subline of the EMT6 tumour now designated EMT6/Ca/VJAC, and it has been described in detail elsewhere (Twentyman & Bleehen, 1975) . The tumour is maintained in alternating in vivo/in vitro passages, regularly returning to frozen stock. Tumours were implanted using cells harvested from the 2nd to 5th in vitro passage after an in vivo passage.
An inoculum of 105 cells in 0-1 ml growth medium was used. Leg tumours were produced by i.m. inoculation in the lower leg, and flank tumours by inoculation intradermally (i.d.) in the previously plucked skin of the flank.
Tumour volumes
Leg tumours.-Volumes were calculated after taking caliper measurements of 2 mutually perpendicular diameters at right angles to the axis of the leg, taking the mean of these and calculating the volume as for a sphere, then subtracting the volume of normal leg. This method was found to be acceptable for tumours greater than 6-0 mm in mean diameter. (Any tumour in which the difference between-diameters exceeded 1 0 mm was discarded.) Leg tumours usually reached a mean diameter of about 8-0 mm by Days 7 or 8, and for "small" leg tumours the mean diameters were restricted to 7-75-8-5 mm, that is, 90-170 mm3. "Large" leg tumours were usually grown by Days 10-11 and the mean diameters were restricted to 10 0-11 25 mm, equivalent to a volume of 350-550 mm3. For "very large" leg tumours the mean diameters were restricted to 12-0-13-75 mm, i.e. 700-1100 mm3.
Flank tumours.-Volumes were calculated by measuring 3 mutually perpendicular axes of the usually ovoid tumour, and calculating the volume according to the method of Watson (1976) . Tumours usually arrived at a volume of about 100 mm3 by Day 9. "Small" flank tumours were used in the volume range 60-140 mm3 and "large" ones in the range 350-550 mm3.
Drugs
Supplies of MISO and its 0-demethylated metabolite Ro 05-9963 (1-(2-nitroimidazolel-yl)-2,3 propandiol) were provided by Roche Laboratories (Welwyn Garden City, Herts). MISO was routinely dissolved in Hanks' balanced salt solution at 25 mg/ml for the high dose (1.0 g/kg) and 2X5 mg/ml for the low dose (100 mg/kg). The solutions were injected i.p. such that a 25g mouse received 1.0 ml. MISO analysed by reversed-phase high-performance liquid chromatography (HPLC) as previously described (Workman et al., 1978 (t4) is given by ln2/Kei. The area under the curve (AUC) of a drug has been widely used as a measure of tissue exposure. The AUCs of plasma or tumour MISO and Ro 05-9963 concentrations were estimated by Simpson's rule. When the AUC for both compounds is converted from jg.h/ml to ,umol.h/ml the AUCs can be summed to give the total nitroimidazole AUC.
RESULTS
Effect of Sagatal on MISO pharrmacokinetics
The dose of Sagatal used to anaesthetize mice also treated with 10 g/kg MISO (e.g. in heating experiments) is 40 mg/kg. The effect of this dose on MISO pharmacokinetics was investigated in nontumour-bearing mice. Previous studies have shown that the ti can be shortened by phenobarbitone pre-E treatment with 100 mg/kg daily for 5 days g before MISO treatment (Workman, 1979) . z Part B in Table I shows that Sagatal has 0 no effect in the induced mice. We also < demonstrated that Sagatal had no All experiments showed a lower tumour MISO and Ro 05-9963 level in heated than unheated tumours, the difference being greater at the earlier times (up to 3 h) (Fig.  3 ). This produced a lower AUC for heated tumours, an effect which is described in greater detail below.
Low-dose studies
In view of the difference in MISO pharmacokinetics at high and low doses, Effect of local heating on core temperature Measurements of rectal temperature, as a measure of core temperature, have been made on unanaesthetized and MISOtreated anaesthetized heated and unheated mice at an ambient temperature of 26-5°C. Unanaesthetized, untreated mice have a rectal temperature of about 38-38-5°C, whereas the temperature of anaesthetized (40 mg/kg Sagatal) mice treated with 1-0 g/kg MISO drops by an average of 5TC during the first hour and then steadily rises during the next 9 h so that it has returned to normal by 10 h after drug administration. Although a dose of 60 mg/kg Sagatal (which produces a similar level of anaesthesia to 40 mg/kg Sagatal in conjunction with 1-0 g/kg MISO-see "Drugs" section) also causes a temperature drop of about 5TC, this effect is relatively short-lived, the minimum temperature being recorded 40 min after the drug is given, and by 2 h after the 5-O34I temperature is within 0 5°C of that of untreated controls. The effect of 1.0 g/kg MISO on unanaesthetized animals is almost the same as on anaesthetized ones, the temperature dropping by an average of 4°C in the first hour. The time scale of recovery is similar to that for anaesthetized mice: normal by 10 h after treatment following a steady rise from 2 h after treatment. The temperatures of locally heated, anaesthetized mice also treated with 1.0 g/kg MISO show more variation between animals, and they rise to a maximum after about 30 min of heating (from 39*5 to 40 5°C) when further anaesthetic is required and the temperature drops to between 38-5 and 39 5°C. It then rises gradually or remains approximately steady for the remaining heating time.
Thus the core temperatures of heated and unheated mice after treatment with 10 g/kg MISO are very different during the hour of heating, differences of up to 7°C being quite likely. After heating, the temperatures of heated animals drop, so that the discrepancy between core temperatures of heated and unheated mice diminishes.
Effect of heat, size and site on high dose MISO levels in tumours
In these experiments MISO levels were ineasured in tumour and plasma at 2 selected times only, 1 and 3 h after injection of 1-0 g/kg of MISO. The effect of heat for 1 h after the injection of MISO in large and small tumours was examined, and also the effect of tumour size in both leg and flank, using 3 sizes of leg tumour and 2 of flank tumour. Small leg and flank tumours were of similar volume, as were large tumours in both sites (see "Experimental" section for sizes used). No flank tumours were heated, but all mice were anaesthetized with Sagatal. All experiments demonstrated the same trend and the results of one are summarized in Table IV . The MISO tumour: plasma ratios are seen to be consistently lower in heated than in control tumours (P<0-01 for 1 h data and P < 0-001 for 3h data). Also, in both flanks and legs, large tumours have a lower ratio than small ones (P < 0 001 for both times) but no further decrease is seen in very large leg tumours. The tumour: plasma ratios in unheated small leg and flank tumours were similar, as might be expected, but the same increase in size decreased the tumour: plasma ratio more in leg tumours than in flank tumours (P < 0-001 for lh data and P < 0-01 for 3h data). Similarly, the effect of heat on large leg tumours appeared to be proportionately greater than on small leg tumours, but this was significant at 3 h only (P > 0.2 for lh data and P < 0-01 for 3h data).
The probabilities quoted above were calculated by carrying out an analysis of variance on log tumour: plasma ratios, considering firstly the effects of heat and size and their interaction, and then the effects of site and size and their interaction. Results of this analysis are given in Table V to illustrate the relative significance of the effects. The effect of size is the most significant, having the greatest F ratio.
Uniformity of MISO distribution in heated and unheated tumours
It has been shown that cell survival is higher in the centre than the periphery of heated tumours with 1.0 g/kg MISO . Although it seemed likely that a higher temperature at the periphery accounted for the lower survival there, it was possible that a nonuniform distribution of MISO throughout the tumour might have contributed to this phenomenon. Experiments were therefore carried out using male mice with leg tumours given 1.0 g/kg MISO and either heated for 1 h in a 44°C waterbath or left at room temperature. All mice were anaesthetized with Sagatal. Tumours were excised 1 h after injection with MISO, i.e. immediately after heating when appropriate, and carefully dissected into peripheral and central areas which were assayed separately. Data from one experiment are shown in Table VI. They TABLE IV Local hyperthermia was found to have very little effect on the plasma pharmacokinetics of MISO. There was, however, a tendency for the plasma MISO t-in locally heated animals to be rather longer at the high dose (1 .0 g/kg) of MISO, but this was not significant in 2/3 experiments, nor at the low dose (100 mg/kg). The increase in t, was due to higher plasma levels at the later times (8-12 h), when no more than 20% of the peak drug concentration remained. As a result, the MISO AUC was not affected. Previous reports have suggested that the toxicity of MISO is related to the AUC (Dische et al., 1977; Workman, 1979) . Our finding that hyperthermia does not affect the plasma AUC of MISO is interesting in view of the increased toxicity of the drug by this treatment (Overgaard, 1979; unpublished results) . This suggests that other factors may also be involved in the toxicity. Our finding that locally applied hyperthermia, which also caused a systemic temperature rise of between 2 and 3°C, has very little effect on the pharmacokinetics of MISO is essentially similar to that of Mimnaugh (1978) on Adriamycin in rabbits. In that study the core temperature of hyperthermic animals was 2 5°C higher than that of controls.
In contrast to the finding that local heating had little effect on systemic MISO pharmacokinetics, this treatment was found to reduce the MISO tumour levels, differences of up to 70% being found in the early samples. Other studies on tissue uptake of drug at raised temperatures deal with normzal tissues, e.g. dog leg (Rochlin et al., 1961) and rabbit skeletal muscle and duodenum (Mimnaugh, 1978) and they both demonstrate a higher level in the heated normal tissue. It seems unlikely that the reduction in MISO concentration could be due to inPeriphery Centre mean 2 x s.e. Mean 2 x s.e. creased oxidative metabolisminthe tumour (which is on average 2°C hotter than the maximum core temperature) because correspondingly higher Ro 05-9963 levels might be expected, yet these were found to be unchanged. However, we cannot rule out the possibility that more rapid metabolism by other routes may be responsible. It is also possible that the decreased MISO concentrations in heated tumours are lower due to a reduction in the blood supply. This might be caused by heat-induced oedema constricting the blood vessels in the leg; oedema is brought about within 30 min of immersion in a 44°C water bath. Alternatively, it may be caused by a reduction in blood flow to the heated tumour, associated with a drop in blood pressure caused by sodium pentobarbitone. We did show that in the absence of heat sodium pentobarbitone did not affect tumour MISO concentration, but were unable to compare heated tumours with and without the anaesthetic. Johnson et at. (1976) (Marmor, 1979) . In these cases, the potential effect must exceed the observed effect, since the heated tumours have received less drug than the controls. This must be considered in evaluating the exploitability of such an enhancement.
The observation that tumour size and implantation site in unheated tumours influence the MISO concentration in those tumours is also significant. It is perhaps to be expected that larger tumours would have lower total levels of drug, because part of their volume is composed of a necrotic centre with no intact blood supply, which will receive drug only by diffusion. Donelli et al. (1977) have shown in intramuscular Lewis lung tumours, for a variety of cytotoxic agents, that drug is mainly to be found in the viable part, with very little in the necrotic parts of the tumour. None the less it is surprising that the same increase in tumour size has more effect on the drug concentration in leg tumours than in flank tumours. This may be due to differences in geometry and hence the relative sizes of necrotic centres in leg and flank tumours with similar calculated volumes. The demonstration that, irrespective of site, large tumours have lower concentrations of drug than small ones may be of importance with regard to reports of investigations with other drugs where small tumours have shown greater sensitivity, estimated by growth delay, than large ones. This phenomenon has been reported for the response of the Lewis lung tumour to cyclophosphamide (Steel & Adams, 1975) and for the response of the P815X2 mastocytoma and the EMT6 tumour to BCNU (Schenken, 1976; Twentyman, 1978) . Perhaps the effect is partly a reflection of the actual tumour drug dose as well as the usually accepted explanation in terms of proliferative state.
The demonstration that MISO levels are the same in monitored and unmonitored tumours shows that the greater cell killing in heated monitored tumours treated with MISO (Honess et al., 1978) cannot be attributed to higher drug levels due to intra-tumoural haemorrhage. It may therefore be caused by better temperature equilibration of the monitored tumours due to conduction along the metal probe within the tumour, or by direct mechanical damage.
The main conclusions from this work are that the pharmacokinetics of MISO are unaffected by sodium pentobarbitone anaesthesia and very slightly affected by hyperthermia at a 44TC water bath temperature for 1 h. However, tumour levels of MISO are reduced. Also tumour levels of MISO in unheated tumours vary according to size and site. It seems unlikely that this phenomenon should be confined to MISO and, if it were shown to occur for other drugs also, it would at least partially account for some of the reports of variation in tumour chemosensitivity with size.
